Portfolio Update

RNS Number : 3593N

Woodford Patient Capital Trust PLC

08 May 2018

 

Woodford Patient Capital Trust plc

(the "Company")

Autolus files for proposed initial public offering in the United States

8 May 2018

Woodford Patient Capital Trust plc, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) ("Autolus") has filed a registration statement on Form F-1 ("Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering ("IPO") in the United States of its American Depositary Shares ("ADSs"), each representing one ordinary share. All ADSs to be sold in the proposed IPO will be offered by Autolus. Autolus intends to apply to list its ADSs on the Nasdaq Global Market under the ticker symbol "AUTL". The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.

The Registration Statement relating to the ADSs has been filed with the SEC but has not yet become effective. The ADSs may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.

The Registration Statement can be accessed through the SEC's EDGAR Database.  WPCT notes that the Registration Statement contains further information relating to Autolus, and further notes that the information includes previously unpublished information relating to Autolus' current clinical trials.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from either of the joint book-running managers for the offering, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at [phone] or by email at [e-mail]

; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at + 1 877 547 6340, or by email [e-mail]

For further information, please contact:

 Four Broadgate

Roland Cross / Jonathan Atkins/ Cara Steinson

020 3697 4200

[e-mail]

LEI: 2138008X94M7OVE73I77

 

END

 

 

PFUBVLFBVEFBBBQ